Perspectives of the non-statin hypolipidemic agents

Pharmacology and Therapeutics

Volumn 127, Issue 1, 2010, Pages 19-40

  Rozman, Damjana ^a   Monostory, Katalin ^b  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b CHEMICAL RESEARCH CENTER   (Hungary)

Author keywords

Cardiovascular disease; Cholesterol; Hyperlipidemia; Hypolipidemic drugs; Liver; Statin

Indexed keywords

4 [2 [1 (4 CHLOROCINNAMYL) 4 PIPERAZINYL]ETHYL]BENZOIC ACID; 7 DEHYDROCHOLESTEROL REDUCTASE INHIBITOR; ANACETRAPIB; ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID SEQUESTRANT; CERIVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COLESEVELAM; DALCETRAPIB; EMPOAMIL BINDING PROTEIN INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAPAQUISTAT; NICOTINIC ACID; OXIDOSQUALENE CYCLASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSUVASTATIN; SIMVASTATIN; SQUALENE EPOXIDASE INHIBITOR; SQUALENE SYNTHASE INHIBITOR; STEROL 14ALPHA DEMETHYLASE INHIBITOR; TORCETRAPIB; TRIPARANOL; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZARAGOZIC ACID C; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BACKACHE; BLINDNESS; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; COGNITIVE DEFECT; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; FLUSHING; GASTROINTESTINAL SYMPTOM; HEART MUSCLE ISCHEMIA; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMPOTENCE; INFLAMMATION; KIDNEY DISEASE; KIDNEY FAILURE; LIPID ABSORPTION; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; MUSCLE CRAMP; MUSCLE DISEASE; MYALGIA; MYOPATHY; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TOXIC HEPATITIS; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; ENZYMOLOGY; FEMALE; INTESTINE ABSORPTION; MALE; METABOLISM; RISK FACTOR;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; CHOLESTEROL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTESTINAL ABSORPTION; MALE; RISK FACTORS; HYPOLIPIDEMIC AGENTS;

EID: 77953535151     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.03.007     Document Type: Review

References (278)

1. Abourbih S., Filion K.B., Joseph L., Schiffrin E.L., Rinfret S., Poirier P., et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: A systematic review. Am J Med 2009, 122(10):962e.1-962.e8.
2. Acimovic J., Lovgren-Sandblom A., Monostory K., Rozman D., Golicnik M., Lutjohann D., et al. Combined gas chromatographic/mass spectrometric analysis of cholesterol precursors and plant sterols in cultured cells. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877(22):2081-2086.
3. Adams C.M., Goldstein J.L., Brown M.S. Cholesterol-induced conformational change in SCAP enhanced by Insig proteins and mimicked by cationic amphiphiles. Proc Natl Acad Sci U S A 2003, 100(19):10647-10652.
4. Alsheikh-Ali A.A., Karas R.H. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am J Cardiol 2007, 99(3):379-381.
5. Alsheikh-Ali A.A., Karas R.H. The safety of niacin in the US Food and Drug Administration adverse event reporting database. Am J Cardiol 2008, 101(8A):9B-13B.
6. Alsheikh-Ali A.A., Maddukuri P.V., Han H., Karas R.H. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: Insights from large randomized statin trials. J Am Coll Cardiol 2007, 50(5):409-418.
7. Altman R. Risk factors in coronary atherosclerosis athero-inflammation: The meeting point. Thromb J 2003, 1(1):4.
8. Altmann S.W., Davis H.R., Zhu L.J., Yao X., Hoos L.M., Tetzloff G., et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303(5661):1201-1204.
9. Armitage J. The safety of statins in clinical practice. Lancet 2007, 370(9601):1781-1790.
10. Bae S.H., Paik Y.K. Cholesterol biosynthesis from lanosterol: development of a novel assay method and characterization of rat liver microsomal lanosterol delta 24-reductase. Biochem J 1997, 326(Pt 2):609-616.
11. Baker S.K. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 2005, 5b:572-580.
12. Barbu V., Roux C., Lambert D., Dupuis R., Gardette J., Maziere J.C., et al. Cholesterol prevents the teratogenic action of AY 9944: Importance of the timing of cholesterol supplementation to rats. J Nutr 1988, 118(6):774-779.
13. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357(21):2109-2122.
14. Baumgart E., Stegmeier K., Schmidt F.H., Fahimi H.D. Proliferation of peroxisomes in pericentral hepatocytes of rat liver after administration of a new hypocholesterolemic agent (BM 15766). Sex-dependent ultrastructural differences. Lab Invest 1987, 56(5):554-564.
15. Bays H., Dujovne C. Colesevelam HCl: A non-systemic lipid-altering drug. Expert Opin Pharmacother 2003, 4(5):779-790.
16. Bays H., Jones P.H. Colesevelam hydrochloride: Reducing atherosclerotic coronary heart disease risk factors. Vasc Health Risk Manag 2007, 3(5):733-742.
17. Bays H.E., Moore P.B., Drehobl M.A., Rosenblatt S., Toth P.D., Dujovne C.A., et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: Pooled analysis of two phase II studies. Clin Ther 2001, 23(8):1209-1230.
18. Bays H.E., Neff D., Tomassini J.E., Tershakovec A.M. Ezetimibe: Cholesterol lowering and beyond. Expert Rev Cardiovasc Ther 2008, 6(4):447-470.
19. Beaird S.L. HMG-CoA reductase inhibitors: Assessing differences in drug interactions and safety profiles. J Am Pharm Assoc (Wash) 2000, 40(5):637-644.
20. Beck L.A., Hosick T.J., Sinensky M. Isoprenylation is required for the processing of the lamin A precursor. J Cell Biol 1990, 110(5):1489-1499.
21. Bell D.S., O'Keefe J.H. Rediscovering bile acid sequestrants. Diabetes Obes Metab 2009, 11(12):1114-1121.
22. Bellosta S., Paoletti R., Corsini A. Safety of statins: Focus on clinical pharmacokinetics and drug interactions. Circulation 2004, 109(23 Suppl 1):III50-III57.
23. Bennati A.M., Schiavoni G., Franken S., Piobbico D., Della Fazia M.A., Caruso D., et al. Disruption of the gene encoding 3beta-hydroxysterol Delta-reductase (Tm7sf2) in mice does not impair cholesterol biosynthesis. FEBS J 2008, 275(20):5034-5047.
24. Berthois Y., Bourrie B., Galiegue S., Vidal H., Carayon P., Martin P.M., et al. SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo. Br J Cancer 2003, 88(3):438-446.
25. Bjorkhem I. Do oxysterols control cholesterol homeostasis?. J Clin Invest 2002, 110(6):725-730.
26. Bloomfield D., Carlson G.L., Sapre A., Tribble D., McKenney J.M., Littlejohn T.W., et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009, 157(2):352-360.
27. Bodor E.T., Offermanns S. Nicotinic acid: An old drug with a promising future. Br J Pharmacol 2008, 153(Suppl 1):S68-S75.
28. Boyle P.J., King A.B., Olansky L., Marchetti A., Lau H., Magar R., et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records. Clin Ther 2002, 24(3):378-396.
29. Braverman N., Lin P., Moebius F.F., Obie C., Moser A., Glossmann H., et al. Mutations in the gene encoding 3 beta-hydroxysteroid-delta 8, delta 7-isomerase cause X-linked dominant Conradi-Hunermann syndrome. Nat Genet 1999, 22(3):291-294.
30. Brinton E.A. Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?. Curr Atheroscler Rep 2008, 10(1):25-32.
31. Brousseau M.E., Schaefer E.J., Wolfe M.L., Bloedon L.T., Digenio A.G., Clark R.W., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350(15):1505-1515.
32. Brown B.G., Zhao X.Q. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 2008, 101(8A):58B-62B.
33. Brown B.G., Stukovsky K.H., Zhao X.Q. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: A meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 2006, 17(6):631-636.
34. Brown M.S., Ze J., Goldstein J.L. Regulated intramembrane proteolysis: A control mechanism conserved from bacteria to human. Cell 2000, 100:391-398.
35. Buhaescu I., Izzedine H. Mevalonate pathway: A review of clinical and therapeutical implications. Clin Biochem 2007, 40(9-10):575-584.
36. Burnett J.R. Drug evaluation: TAK-475-an oral inhibitor of squalene synthase for hyperlipidemia. Curr Opin Investig Drugs 2006, 7(9):850-856.
37. Burton P.M., Swinney D.C., Heller R., Dunlap B., Chiou M., Malonzo E., et al. Azalanstat (RS-21607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity. Biochem Pharmacol 1995, 50(4):529-544.
38. Buttke T.M., Folks T.M. Complete replacement of membrane cholesterol with 4, 4-, 14-trimethyl sterols in a human T cell line defective in lanosterol demethylation. J Biol Chem 1992, 267(13):8819-8826.
39. Byskov A.G., Andersen C.Y., Nordholm L., Thøgersen H., Xia G., Wassmann O., et al. Chemical structure of sterols that activate oocyte meiosis. Nature 1995, 374(6522):559-562.
40. Campia I., Lussiana C., Pescarmona G., Ghigo D., Bosia A., Riganti C. Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis. Br J Pharmacol 2009, 158(7):1777-1786.
41. Carbonell T., Freire E. Binding thermodynamics of statins to HMG-CoA reductase. Biochemistry 2005, 44(35):11741-11748.
42. Castelli W.P., Anderson K., Wilson P.W., Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992, 2(1-2):23-28.
43. Cenedella R.J. Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids 2009, 44(6):477-487.
44. Chapman M.J., Le Goff W., Guerin M., Kontush A. Cholesteryl ester transfer protein: At the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010, 31(2):149-164.
45. Chevy F., Illien F., Wolf C., Roux C. Limb malformations of rat fetuses exposed to a distal inhibitor of cholesterol biosynthesis. J Lipid Res 2002, 43(8):1192-1200.
46. Chugh A., Ray A., Gupta J.B. Squalene epoxidase as hypocholesterolemic drug target revisited. Prog Lipid Res 2003, 42(1):37-50.
47. Clarke G.A., Bouchard G., Paigen B., Carey M.C. Cholesterol synthesis inhibition distal to squalene upregulates biliary phospholipid secretion and counteracts cholelithiasis in the genetically prone C57L/J mouse. Gut 2004, 53(1):136-142.
48. Clayton P.T. Disorders of cholesterol biosynthesis. Arch Dis Child 1998, 78:185-189.
49. Conklin D.J., Barski O.A., Lesgards J.F., Juvan P., Rezen T., Rozman D., et al. Acrolein consumption induces systemic dyslipidemia and lipoprotein modification. Toxicol Appl Pharmacol 2010, 243(1):1-12.
50. Correa-Cerro L.S., Porter F.D. 3beta-hydroxysterol Delta7-reductase and the Smith-Lemli-Opitz syndrome. Mol Genet Metab 2005, 84(2):112-126.
51. Corsini A., Windler E., Farnier M. Colesevelam hydrochloride: Usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. Eur J Cardiovasc Prev Rehabil 2009, 16(1):1-9.
52. Cotman M., Jezek D., Fon Tacer K., Frangez R., Rozman D. A functional cytochrome P450 lanosterol 14{alpha}-demethylase CYP51 enzyme in the acrosome: Transport through the Golgi and synthesis of meiosis activating sterols. Endocrinology 2004, 145:1419-1426.
53. Darnet S., Rahier A. Enzymological properties of sterol-C4-methyl-oxidase of yeast sterol biosynthesis. Biochim Biophys Acta 2003, 1633(2):106-117.
54. Darnet S., Rahier A. Plant sterol biosynthesis: Identification of two distinct families of sterol 4alpha-methyl oxidases. Biochem J 2004, 378(Pt 3):889-898.
55. Davidson M.H. Reducing residual risk for patients on statin therapy: The potential role of combination therapy. Am J Cardiol 2005, 96(9A):3K-13K. discussion 34K-35K.
56. Davidson M.H. The use of colesevelam hydrochloride in the treatment of dyslipidemia: A review. Expert Opin Pharmacother 2007, 8(15):2569-2578.
57. Davidson M.H. Niacin use and cutaneous flushing: Mechanisms and strategies for prevention. Am J Cardiol 2008, 101(8A):14B-19B.
58. Davidson M.H., Robinson J.G. Safety of aggressive lipid management. J Am Coll Cardiol 2007, 49(17):1753-1762.
59. Davidson M.H., Armani A., McKenney J.M., Jacobson T.A. Safety considerations with fibrate therapy. Am J Cardiol 2007, 99(6A):3C-18C.
60. Davidson M.H., Dicklin M.R., Maki K.C., Kleinpell R.M. Colesevelam hydrochloride: A non-absorbed, polymeric cholesterol-lowering agent. Expert Opin Investig Drugs 2000, 9(11):2663-2671.
61. Davidson M.H., Dillon M.A., Gordon B., Jones P., Samuels J., Weiss S., et al. Colesevelam hydrochloride (cholestagel): A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999, 159(16):1893-1900.
62. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 109(23 Suppl 1):III39-III43.
63. Davignon J., Leiter L.A. Ongoing clinical trials of the pleiotropic effects of statins. Vasc Health Risk Manag 2005, 1(1):29-40.
64. Davis H.R., Veltri E.P. Zetia: Inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 2007, 14(3):99-108.
65. Davis H.R., Zhu L.J., Hoos L.M., Tetzloff G., Maguire M., Liu J., et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 2004, 279(32):33586-33592.
66. Debeljak N., Fink M., Rozman D. Many facets of mammalian lanosterol 14alpha-demethylase from the evolutionarily conserved cytochrome P450 family CYP51. Arch Biochem Biophys 2003, 409(1):159-171.
67. den Dekker W.K., Cheng C., Pasterkamp G., Duckers H.J. Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis 2010, 209(2):314-320.
68. Di Stasi D., Vallacchi V., Campi V., Ranzani T., Daniotti M., Chiodini E., et al. DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress-induced apoptosis. Int J Cancer 2005, 115(2):224-230.
69. Digby J.E., Lee J.M., Choudhury R.P. Nicotinic acid and the prevention of coronary artery disease. Curr Opin Lipidol 2009, 20(4):321-326.
70. Do R., Kiss R.S., Gaudet D., Engert J.C. Squalene synthase: A critical enzyme in the cholesterol biosynthesis pathway. Clin Genet 2009, 75(1):19-29.
71. Dochi M., Suwazono Y., Sakata K., Okubo Y., Oishi M., Tanaka K., et al. Shift work is a risk factor for increased total cholesterol level: A 14-year prospective cohort study in 6886 male workers. Occup Environ Med 2009, 66(9):592-597.
72. Draeger A., Monastyrskaya K., Mohaupt M., Hoppeler H., Savolainen H., Allemann C., et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006, 210(1):94-102.
73. Dujovne C.A., Ettinger M.P., McNeer J.F., Lipka L.J., LeBeaut A.P., Suresh R., et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002, 90(10):1092-1097.
74. Duniec-Dmuchowski Z., Fang H.L., Strom S.C., Ellis E., Runge-Morris M., Kocarek T.A. Human pregnane X receptor activation and CYP3A4/CYP2B6 induction by 2, 3-oxidosqualene:lanosterol cyclase inhibition. Drug Metab Dispos 2009, 37(4):900-908.
75. Elsayed R.K., Evans J.D. Emerging lipid-lowering drugs: Squalene synthase inhibitors. Expert Opin Emerg Drugs 2008, 13(2):309-322.
76. Endo A. The origin of the statins. 2004. Atheroscler Suppl 2004, 5(3):125-130.
77. Escobar C., Echarri R., Barrios V. Relative safety profiles of high dose statin regimens. Vasc Health Risk Manag 2008, 4(3):525-533.
78. Favre B., Ryder N.S. Differential inhibition of fungal amd mammalian squalene epoxidases by the benzylamine SDZ SBA 586 in comparison with the allylamine terbinafine. Arch Biochem Biophys 1997, 340(2):265-269.
79. Fazio S. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: A role for combination fibrate therapy. Clin Ther 2008, 30(2):294-306.
80. Feige J.N., Gelman L., Michalik L., Desvergne B., Wahli W. From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006, 45(2):120-159.
81. Fink M., Acimovic J., Rezen T., Tansek N., Rozman D. Cholesterogenic lanosterol 14alpha-demethylase (CYP51) is an immediate early response gene. Endocrinology 2005, 146(12):5321-5331.
82. Fitzky B.U., Witsch-Baumgartner M., Erdel M., Lee J.N., Paik Y.K., Glossmann H., et al. Mutations in the Delta7-sterol reductase gene in patients with the Smith-Lemli-Opitz syndrome. Proc Natl Acad Sci U S A 1998, 95(14):8181-8086.
83. Fliesler S.J., Peachey N.S., Richards M.J., Nagel B.A., Vaughan D.K. Retinal degeneration in a rodent model of Smith-Lemli-Opitz syndrome: Electrophysiologic, biochemical, and morphologic features. Arch Ophthalmol 2004, 122(8):1190-1200.
84. Florentin M., Liberopoulos E.N., Elisaf M.S. Ezetimibe-associated adverse effects: What the clinician needs to know. Int J Clin Pract 2008, 62(1):88-96.
85. Fon Tacer K., Haugen T.B., Baltsen M., Debeljak N., Rozman D. Tissue-specific transcriptional regulation of the cholesterol biosynthetic pathway leads to accumulation of testis meiosis activation sterol T-MAS. J Lipid Res 2002, 43:82-89.
86. Friesen J.A., Rodwell V.W. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome Biol 2004, 5(11):248.
87. Furberg C.D., Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001, 2(5):205-207.
88. Gagne C., Bays H.E., Weiss S.R., Mata P., Quinto K., Melino M., et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002, 90(10):1084-1091.
89. Ganji S.H., Tavintharan S., Zhu D., Xing Y., Kamanna V.S., Kashyap M.L. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004, 45(10):1835-1845.
90. Garcia-Calvo M., Lisnock J., Bull H.G., Hawes B.E., Burnett D.A., Braun M.P., et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 2005, 102(23):8132-8137.
91. Giera M., Renard D., Plössl F., Bracher F. Lathosterol side chain amides: A new class of human lathosterol oxidase inhibitors. Steroids 2008, 73(3):299-308.
92. Goldberg A.C., Sapre A., Liu J., Capece R., Mitchel Y.B. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004, 79(5):620-629.
93. Goldstein J.L., Brown M.S. The LDL receptor. Arterioscler Thromb Vasc Biol 2009, 29(4):431-438.
94. Goldstein J.L., DeBose-Boyd R.A., Brown M.S. Protein sensors for membrane sterols. Cell 2006, 124(1):35-46.
95. Gong Y., Lee J.N., Lee P.C., Goldstein J.L., Brown M.S., Ye J. Sterol-regulated ubiquitination and degradation of Insig-1 creates a convergent mechanism for feedback control of cholesterol synthesis and uptake. Cell Metab 2006, 3(1):15-24.
96. Greeve I., Hermans-Borgmeyer I., Brellinger C., Kasper D., Gomez-Isla T., Behl C., et al. The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J Neurosci 2000, 20(19):7345-7352.
97. Grigore L., Norata G.D., Catapano A.L. Combination therapy in cholesterol reduction: Focus on ezetimibe and statins. Vasc Health Risk Manag 2008, 4(2):267-278.
98. Grinstead G.F., Gaylor J.L.J. Total enzymic synthesis of cholesterol from 4, 4, 14 alpha-trimethyl-5 alpha-cholesta-8, 24-dien-3 beta-ol. Solubilization, resolution, and reconstitution of delta 7-sterol 5-desaturase. J Biol Chem 1982, 257(23):13937-13944.
99. Grøndahl C., Ottesen J.L., Lessl M., Faarup P., Murray A., Grønvald F.C., et al. Meiosis-activating sterol promotes resumption of meiosis in mouse oocytes cultured in vitro in contrast to related oxysterols. Biol Reprod 1998, 58(5):1297-1302.
100. Guengerich F.P., Hosea N.A., Parikh A., Bell-Parikh C., Johnson W.W., J., G.E.M., et al. Twenty years of biochemistry of human P450s: Purification, expression, mechanism, and relevance to drugs. Drug Metab Dispos 1998, 26(12):1175-1178.
101. Gupta N., Porter T.D. Inhibition of human squalene monooxygenase by selenium compounds. J Biochem Mol Toxicol 2002, 16(1):18-23.
102. Halder S., Fink M., Waterman M., Rozman D. A cAMP responsive element binding site is essential for sterol regulation of the human lanosterol 14-demethylase gene (CYP51). Mol Endo 2002, 16:1853-1863.
103. Hamelin B.A., Turgeon J. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998, 19(1):26-37.
104. Handschin C., Podvinec M., Amherd R., Looser R., Ourlin J.-C., Meyer U.A. Cholesterol and bile acids regulate xenosensor signaling in drug-mediated induction of cytochromes P450. J Biol Chem 2002, 277(33):29561-29567.
105. Hausenloy D.J., Yellon D.M. Targeting residual cardiovascular risk: Raising high-density lipoprotein cholesterol levels. Postgrad Med J 2008, 84(997):590-598.
106. Hayashi T., Yokote K., Saito Y., Iguchi A. Pitavastatin: Efficacy and safety in intensive lipid lowering. Expert Opin Pharmacother 2007, 8(14):2315-2327.
107. Herman R.J. Drug interactions and the statins. Cmaj 1999, 161(10):1281-1286.
108. Hihi A.K., Michalik L., Wahli W. PPARs: Transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci 2002, 59(5):790-798.
109. Hiyoshi H., Yanagimachi M., Ito M., Yasuda N., Okada T., Ikuta H., et al. Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes. J Lipid Res 2003, 44(1):128-135.
110. Holdgate G.A., Ward W.H., McTaggart F. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans 2003, 31(Pt 3):528-531.
111. Holmer L., Pezhman A., Worman H.J. The human lamin B receptor/sterol reductase multigene family. Genomics 1998, 54(3):469-476.
112. Honda A., Tint G.S., Shefer S., Batta A.K., Honda M., Salen G. Effect of YM 9429, a potent teratogen, on cholesterol biosynthesis in cultured cells and rat liver microsomes. Steroids 1996, 61(9):544-548.
113. Horton J.D., Goldstein J.L., Brown M.S. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002, 109(9):1125-1131.
114. Hou R., Goldberg A.C. Lowering low-density lipoprotein cholesterol: Statins, ezetimibe, bile acid sequestrants, and combinations: Comparative efficacy and safety. Endocrinol Metab Clin North Am 2009, 38(1):79-97.
115. Huang Z., Inazu A., Nohara A., Higashikata T., Mabuchi H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond) 2002, 103(6):587-594.
116. Huff M.W., Telford D.E. Lord of the rings-the mechanism for oxidosqualene: Lanosterol cyclase becomes crystal clear. Trends Pharmacol Sci 2005, 26(7):335-340.
117. Hulten E., Jackson J.L., Douglas K., George S., Villines T.C. The effect of early, intensive statin therapy on acute coronary syndrome: A meta-analysis of randomized controlled trials. Arch Intern Med 2006, 166(17):1814-1821.
118. Insull W., Davidson M.H., Demke D.M., Dujovne C.A., Eckert S.M., Ginsberg D., et al. The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis 1995, 112(2):223-235.
119. Istvan E.S. Bacterial and mammalian HMG-CoA reductases: Related enzymes with distinct architectures. Curr Opin Struct Biol 2001, 11(6):746-751.
120. Istvan E.S. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am Heart J 2002, 144(6 Suppl):S27-S32.
121. Istvan E.S. Statin inhibition of HMG-CoA reductase: A 3-dimensional view. Atheroscler Suppl 2003, 4(1):3-8.
122. Istvan E.S., Deisenhofer J. The structure of the catalytic portion of human HMG-CoA reductase. Biochim Biophys Acta 2000, 1529(1-3):9-18.
123. Istvan E.S., Palnitkar M., Buchanan S.K., Deisenhofer J. Crystal structure of the catalytic portion of human HMG-CoA reductase: Insights into regulation of activity and catalysis. Embo J 2000, 19(5):819-830.
124. Jacobson T.A. Toward "pain-free" statin prescribing: Clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008, 83(6):687-700.
125. Jacobson T.A. Myopathy with statin-fibrate combination therapy: Clinical considerations. Nat Rev Endocrinol 2009, 5(9):507-518.
126. Jacobson T.A., Armani A., McKenney J.M., Guyton J.R. Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 2007, 99(6A):47C-55C.
127. Jamal S.M., Eisenberg M.J., Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 2004, 147(6):956-965.
128. Jones P.H. Expert perspective: Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering. Am J Cardiol 2008, 102(12A):41L-47L.
129. Jones P.H., Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate+statin versus gemfibrozil+any statin. Am J Cardiol 2005, 95(1):120-122.
130. Joukhadar C., Klein N., Prinz M., Schrolnberger C., Vukovich T., Wolzt M., et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001, 85(1):47-51.
131. Jungnickel P.W., Cantral K.A., Maloley P.A. Pravastatin: A new drug for the treatment of hypercholesterolemia. Clin Pharm 1992, 11(8):677-689.
132. Kajinami K., Takekoshi N., Saito Y. Pitavastatin: Efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2003, 21(3):199-215.
133. Kamanna V.S., Kashyap M.L. Mechanism of action of niacin. Am J Cardiol 2008, 101(8A):20B-26B.
134. Kantola T., Kivistö K.T., Neuvonen P.J. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998, 64(2):177-182.
135. Kapur N.K., Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag 2008, 4(2):341-353.
136. Kashani A., Phillips C.O., Foody J.M., Wang Y., Mangalmurti S., Ko D.T., et al. Risks associated with statin therapy: A systematic overview of randomized clinical trials. Circulation 2006, 114(25):2788-2797.
137. Kashani A., Sallam T., Bheemreddy S., Mann D.L., Wang Y., Foody J.M. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol 2008, 101(11):1606-1613.
138. Kavey R.E., Daniels S.R., Lauer R.M., Atkins D.L., Hayman L.L., Taubert K. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 2003, 107(11):1562-1566.
139. Kawata S., Trzaskos J.M., Gaylor J.L. Microsomal enzymes of cholesterol biosynthesis from lanosterol. Purification and characterization of delta 7-sterol 5-desaturase of rat liver microsomes. J Biol Chem 1985, 260(11):6609-6617.
140. Kearney P.M., Blackwell L., Collins R., Keech A., Simes J., Peto R., Armitage J., Baigent C. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 2008, 371(9607):117-125.
141. Kim C.K., Jeon K.I., Lim D.M., Johng T.N., Trzaskos J.M., Gaylor J.L., et al. Cholesterol biosynthesis from lanosterol: Regulation and purification of rat hepatic sterol 14-reductase. Biochim Biophys Acta 1995, 1259(1):39-48.
142. Knopp R.H., Gitter H., Truitt T., Bays H., Manion C.V., Lipka L.J., et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003, 24(8):729-741.
143. Koh C.H., Cheung N.S. Cellular mechanism of U18666A-mediated apoptosis in cultured murine cortical neurons: Bridging Niemann-Pick disease type C and Alzheimer's disease. Cell Signal 2006, 18(11):1844-1853.
144. Koh K.K., Quon M.J., Rosenson R.S., Chung W.J., Han S.H. Vascular and metabolic effects of treatment of combined hyperlipidemia: Focus on statins and fibrates. Int J Cardiol 2008, 124(2):149-159.
145. Konig A., Happle R., Bornholdt D., Engel H., Grzeschik K.H. Mutations in the NSDHL gene, encoding a 3beta-hydroxysteroid dehydrogenase, cause CHILD syndrome. Am J Med Genet 2000, 90(4):339-346.
146. Kontush A., Guerin M., Chapman M.J. Spotlight on HDL-raising therapies: Insights from the torcetrapib trials. Nat Clin Pract Cardiovasc Med 2008, 5(6):329-336.
147. Korosec T., Acimovic J., Seliskar M., Kocjan D., Tacer K.F., Rozman D., et al. Novel cholesterol biosynthesis inhibitors targeting human lanosterol 14alpha-demethylase (CYP51). Bioorg Med Chem 2008, 16(1):209-221.
148. Kosoglou T., Statkevich P., Johnson-Levonas A.O., Paolini J.F., Bergman A.J., Alton K.B. Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005, 44(5):467-494.
149. Krishna R., Anderson M.S., Bergman A.J., Jin B., Fallon M., Cote J., et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: Two double-blind, randomised placebo-controlled phase I studies. Lancet 2007, 370(9603):1907-1914.
150. Krukemyer J.J., Talbert R.L. Lovastatin: A new cholesterol-lowering agent. Pharmacotherapy 1987, 7(6):198-210.
151. Laden B.P., Tang Y., Porter T.D. Cloning, heterologous expression, and enzymological characterization of human squalene monooxygenase. Arch Biochem Biophys 2000, 374(2):381-388.
152. Laggner C., Schieferer C., Fiechtner B., Poles G., Hoffmann R.D., Glossmann H., et al. Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening. J Med Chem 2005, 48(15):4754-4764.
153. Lamb D.C., Kelly D.E., Waterman M.R., Stromstedt M., Rozman D., Kelly S.L. Characteristics of the heterologously expressed human lanosterol 14alpha-demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candida albicans CYP51 with azole antifungal agents. Yeast 1999, 15(9):755-763.
154. LaRosa J.C. Low-density lipoprotein cholesterol reduction: The end is more important than the means. Am J Cardiol 2007, 100(2):240-242.
155. Lee A.J., Maddix D.S. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001, 35(1):26-31.
156. Leiter L.A., Bays H., Conard S., Bird S., Rubino J., Hanson M.E., et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008, 102(11):1495-1501.
157. Lecain E., Chenivesse X., Spagnoli R., Pompon D. Cloning by metabolic interference in yeast and enzymatic characterization of Arabidopsis thaliana sterol delta 7-reductase. J Biol Chem 1996, 271(18):10866-10873.
158. Lepesheva G.I., Park H.W., Hargrove T.Y., Vanhollebeke B., Wawrzak Z., Harp J.M., et al. Crystal structures of Trypanosoma brucei sterol 14 alpha-demethylase and implications for selective treatment of human infections. J Biol Chem 2010, 285(3):1773-1780.
159. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005, 45:89-118.
160. Libby P. Inflammation in atherosclerosis. Nature 2002, 420(6917):868-874.
161. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis from pathophysiology to practice. J Am Coll Cardiol 2009, 54(23):2129-2138.
162. Lilja J.J., Kivisto K.T., Neuvonen P.J. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther 2000, 68(4):384-390.
163. Liu X.Y., Dangel A.W., Kelley R.I., Zhao W., Denny P., Botcherby M., et al. The gene mutated in bare patches and striated mice encodes a novel 3beta-hydroxysteroid dehydrogenase. Nat Genet 1999, 22(2):182-187.
164. Lutjohann D., Marinova M., Schneider B., Oldenburg J., von Bergmann K., Bieber T., et al. 4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man. Int J Clin Pharmacol Ther 2009, 47(12):709-715.
165. Maas R., Boger R.H. Old and new cardiovascular risk factors: From unresolved issues to new opportunities. Atheroscler Suppl 2003, 4(4):5-17.
166. Maeda K., Ieiri I., Yasuda K., Fujino A., Fujiwara H., Otsubo K., et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 2006, 79(5):427-439.
167. Marcoff L., Thompson P.D. The role of coenzyme Q10 in statin-associated myopathy: A systematic review. J Am Coll Cardiol 2007, 49(23):2231-2237.
168. Marijanovic Z., Laubner D., Moeller G., Gege C., Husen B., Adamski J., et al. Closing the gap: Identification of human 3-ketosteroid reductase, the last unknown enzyme of mammalian cholesterol biosynthesis. Mol Endocrinol 2003, 17(9):1715-1725.
169. Martin J.H., Krum H. Statins and clinical outcomes in heart failure. Clin Sci (Lond) 2007, 113(3):119-127.
170. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl 2003, 4(1):9-14.
171. McTaggart F., Buckett L., Davidson R., Holdgate G., McCormick A., Schneck D., et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001, 87(5A):28B-32B.
172. McTavish D., Sorkin E.M. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1991, 42(1):65-89.
173. Melian E.B., Plosker G.L. Colesevelam. Am J Cardiovasc Drugs 2001, 1(2):141-146. discussion 147-148.
174. Michalik L., Desvergne B., Wahli W. Peroxisome proliferator-activated receptors beta/delta: Emerging roles for a previously neglected third family member. Curr Opin Lipidol 2003, 14(2):129-135.
175. Mo C., Valachovic M., Randall S.K., Nickels J.T., Bard M. Protein-protein interactions among C-4 demethylation enzymes involved in yeast sterol biosynthesis. Proc Natl Acad Sci U S A 2002, 99(15):9739-9744.
176. Moebius F.F., Fitzky B.U., Lee J.N., Paik Y.K., Glossmann H. Molecular cloning and expression of the human delta7-sterol reductase. Proc Natl Acad Sci U S A 1998, 95(4):1899-1902.
177. Moebius F.F., Fitzky B.U., Wietzorrek G., Haidekker A., Eder A., Glossmann H. Cloning of an emopamil-binding protein (EBP)-like protein that lacks sterol delta8-delta7 isomerase activity. Biochem J 2003, 374(Pt 1):229-237.
178. Moebius F.F., Striessnig J., Glossmann H. The mysteries of sigma receptors: New family members reveal a role of cholesterol synthesis. TIPS 1997, 19:67-70.
179. Mohaupt M.G., Karas R.H., Babiychuk E.B., Sanchez-Freire V., Monastyrskaya K., Iyer L., et al. Association between statin-associated myopathy and skeletal muscle damage. Cmaj 2009, 181(1-2):E11-E18.
180. Monostory K., Pascussi J.-M., Szabó P., Temesvári M., K-halmy K., Acimovic J., et al. Drug-interaction potential of 2-((3, 4-(dichlorophenethyl(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the novel non-statin type cholesterol lowering agent. Drug Metab Dispos 2009, 37(1):375-385.
181. Mukhtar R.Y., Reid J., Reckless J.P. Pitavastatin. Int J Clin Pract 2005, 59(2):239-252.
182. Muscari A., Puddu G.M., Puddu P. Lipid-lowering drugs: Are adverse effects predictable and reversible?. Cardiology 2002, 97(3):115-121.
183. Nakamura S. Total synthesis of the squalene synthase inhibitor zaragozic acid C. Chem Pharm Bull (Tokyo) 2005, 53(1):1-10.
184. Neeli H., Gadi R., Rader D.J. Managing diabetic dyslipidemia: Beyond statin therapy. Curr Diab Rep 2009, 9(1):11-17.
185. Neuvonen P.J., Backman J.T., Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 2008, 47(7):463-474.
186. Neuvonen P.J., Niemi M., Backman J.T. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther 2006, 80(6):565-581.
187. Nicholls S.J., Tuzcu E.M., Brennan D.M., Tardif J.C., Nissen S.E. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: Insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008, 118(24):2506-2514.
188. Nissen S.E., Tardif J.C., Nicholls S.J., Revkin J.H., Shear C.L., Duggan W.T., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356(13):1304-1316.
189. Noé J., Portmann R., Brun M.E., Funk C. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 2007, 35(8):1308-1314.
190. O'Brien W.T., Xu G., Batta A., Tint G.S., Salen G., Dyer C.A., et al. Developmental sensitivity of associative learning to cholesterol synthesis inhibitors. Behav Brain Res 2002, 129(1-2):141-152.
191. Ohashi M., Mizushima N., Kabeya Y., Yoshimori T. Localization of mammalian NAD(P)H steroid dehydrogenase-like protein on lipid droplets. J Biol Chem 2003, 278(38):36819-36829.
192. Ohnesorg T., Keller B., Hrabe de Angelis M., Adamski J. Transcriptional regulation of human and murine 17beta-hydroxysteroid dehydrogenase type-7 confers its participation in cholesterol biosynthesis. J Mol Endocrinol 2006, 37(1):185-197.
193. Okazaki H., Tazoe F., Okazaki S., Isoo N., Tsukamoto K., Sekiya M., et al. Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver. J Lipid Res 2006, 47(9):1950-1958.
194. Olansky L., Marchetti A., Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: Comparative subgroup analyses of glycemic control and blood lipid levels. Clin Ther 2003, 25(Suppl B):B64-B80.
195. Ourlin J.C., Lasserre F., Pineau T., Fabre J.M., Sa-Cunha A., Maurel P., et al. The small heterodimer partner interacts with the pregnane X receptor and represses its transcriptional activity. Mol Endocrinol 2003, 17(9):1693-1703.
196. Palmer C.N., Hsu M.H., Griffin K.J., Raucy J.L., Johnson E.F. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol 1998, 53(1):14-22.
197. Pappu A.S., Illingworth D.R. The effects of lovastatin and simvastatin on the diurnal periodicity of plasma mevalonate concentrations in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2002, 165(1):137-144.
198. Parent N., Winstall E., Beauchemin M., Paquet C., Poirier G.G., Bertrand R. Proteomic analysis of enriched lysosomes at early phase of camptothecin-induced apoptosis in human U-937 cells. J Proteomics 2009, 72(6):960-973.
199. Patel T.N., Shishehbor M.H., Bhatt D.L. A review of high-dose statin therapy: Targeting cholesterol and inflammation in atherosclerosis. Eur Heart J 2007, 28(6):664-672.
200. Pedretti A., Bocci E., Maggi R., Vistoli G. Homology modelling of human DHCR24 (seladin-1) and analysis of its binding properties through molecular docking and dynamics simulations. Steroids 2008, 73(7):708-719.
201. Peri A., Danza G., Benvenuti S., Luciani P., Deledda C., Rosati F., et al. New insights on the neuroprotective role of sterols and sex steroids: The seladin-1/DHCR24 paradigm. Front Neuroendocrinol 2009, 30(2):119-129.
202. Podust L.M., Poulos T.L., Waterman M.R. Crystal structure of cytochrome P450 14alpha-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci U S A 2001, 98(6):3068-3073.
203. Polonsky T.S., Davidson M.H. Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Am J Cardiol 2008, 101(8A):27B-35B.
204. Preiss D., Sattar N. Lipids, lipid modifying agents and cardiovascular risk: A review of the evidence. Clin Endocrinol (Oxf) 2009, 70(6):815-828.
205. Prieur X., Roszer T., Ricote M. Lipotoxicity in macrophages: Evidence from diseases associated with the metabolic syndrome. Biochim Biophys Acta 2010, 1801(3):327-337.
206. Prueksaritanont T., Tang C., Qiu Y., Mu L., Subramanian R., Lin J.H. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002, 30(11):1280-1287.
207. Prueksaritanont T., Zhao J.J., Ma B., Roadcap B.A., Tang C., Qiu Y., et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002, 301(3):1042-1051.
208. Raasch R.H. Pravastatin sodium, a new HMG-CoA reductase inhibitor. Dicp 1991, 25(4):388-394.
209. Radhakrishnan A., Goldstein J.L., McDonald J.G., Brown M.S. Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: A delicate balance. Cell Metab 2008, 8(6):512-521.
210. Rahier A., Darnet S., Bouvier F., Camara B., Bard M. Molecular and enzymatic characterizations of novel bifunctional 3beta-hydroxysteroid dehydrogenases/C-4 decarboxylases from Arabidopsis thaliana. J Biol Chem 2006, 281(37):27264-27277.
211. Rallidis L.S., Lekakis J., Kremastinos D.T. Current questions regarding the use of statins in patients with coronary heart disease. Int J Cardiol 2007, 122(3):188-194.
212. Repetto M., Maziere J.C., Citadelle D., Dupuis R., Meier M., Biade S., et al. Teratogenic effect of the cholesterol synthesis inhibitor AY 9944 on rat embryos in vitro. Teratology 1990, 42(6):611-618.
213. Rezen T., Debeljak N., Kordis D., Rozman D. New aspects on lanosterol 14alpha-demethylase and cytochrome P450 evolution: Lanosterol/cycloartenol diversification and lateral transfer. J Mol Evol 2004, 59(1):51-58.
214. Rezen T., Juvan P., Fon Tacer K., Kuzman D., Roth A., Pompon D., et al. The Sterolgene v0 cDNA microarray: A systemic approach to studies of cholesterol homeostasis and drug metabolism. BMC Genomics 2008, 9:76.
215. Rezen T., Tamasi V., Lovgren-Sandblom A., Bjorkhem I., Meyer U.A., Rozman D. Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse livers. BMC Genomics 2009, 10:384.
216. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359(21):2195-2207.
217. Roberti R., Bennati A.M., Galli G., Caruso D., Maras B., Aisa C., et al. Cloning and expression of sterol Delta 14-reductase from bovine liver. Eur J Biochem 2002, 269(1):283-290.
218. Rogers J.D., Zhao J., Liu L., Amin R.D., Gagliano K.D., Porras A.G., et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther 1999, 66(4):358-366.
219. Romanuik T.L., Ueda T., Le N., Haile S., Yong T.M., Thomson T., et al. Novel biomarkers for prostate cancer including noncoding transcripts. Am J Pathol 2009, 175(6):2264-2276.
220. Rossi M., D'Armiento M., Parisi I., Ferrari P., Hall C.M., Cervasio M., et al. Clinical phenotype of lathosterolosis. Am J Med Genet A 2007, 143A(20):2371-2381.
221. Rowe A.H., Argmann C.A., Edwards J.Y., Sawyez C.G., Morand O.H., Hegele R.A., et al. Enhanced synthesis of the oxysterol 24(S), 25-epoxycholesterol in macrophages by inhibitors of 2, 3-oxidosqualene:lanosterol cyclase: A novel mechanism for the attenuation of foam cell formation. Circ Res 2003, 93(8):717-725.
222. Rozman D., Waterman M.R. Lanosterol 14a-demthylase (CYP51) and spermatogenesis. Drug Metab Dispos 1998, 26(12):1199-1201.
223. Rozman D., Cotman M., Frangez R. Lanosterol 14alpha-demethylase and MAS sterols in mammalian gametogenesis. Mol Cell Endocrinol 2002, 187(1-2):179-187.
224. Rozman D., Fink M., Fimia G.M., Sassone-Corsi P., Waterman M.R. Cyclic adenosine 3-, 5β-monophosphate(cAMP)/cAMP-responsive element modulator (CREM)-dependent regulation of cholesterogenic lanosterol 14alpha-demethylase (CYP51) in spermatids. Mol Endocrinol 1999, 13(11):1951-1962.
225. Rozman D., Seliskar M., Cotman M., Fink M. Pre-cholesterol precursors in gametogenesis. Mol Cell Endocrinol 2005, 234(1-2):47-56.
226. Rozman D., Strömstedt M., Tsui L.-C., Scherer S.W., Waterman M.R. Structure and mapping of the human lanosterol 14β-demethylase gene (CYP51) encoding the cytochrome P450 involved in cholesterol biosynthesis; comparison of exon/intron organization with other mammalian and fungal CYP genes. Genomics 1996, 38:371-381.
227. Rozman D., Stromstedt M., Waterman M.R. The three human cytochrome P450 lanosterol 14 alpha-demethylase (CYP51) genes reside on chromosomes 3, 7, and 13: Structure of the two retrotransposed pseudogenes, association with a line-1 element, and evolution of the human CYP51 family. Arch Biochem Biophys 1996, 333(2):466-474.
228. Russell D.W. Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res 2009, 50(Suppl):S120-S125.
229. Sakakibara J., Watanabe R., Kanai Y., Ono T. Molecular cloning and expression of rat squalene epoxidase. J Biol Chem 1995, 270(1):17-20.
230. Salen G., Shefer S., Batta A.K., Tint G.S., Xu G., Honda A., et al. Abnormal cholesterol biosynthesis in the Smith-Lemli-Opitz syndrome. J Lipid Res 1996, 37:1169-1180.
231. Sanossian N., Ovbiagele B. Drug insight: Translating evidence on statin therapy into clinical benefits. Nat Clin Pract Neurol 2008, 4(1):43-49.
232. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam Clin Pharmacol 2005, 19(1):117-125.
233. Scharnagl H., Marz W. New lipid-lowering agents acting on LDL receptors. Curr Top Med Chem 2005, 5(3):233-242.
234. Seliskar M., Kosir R., Rozman D. Expression of microsomal lanosterol 14alpha-demethylase (CYP51) in an engineered soluble monomeric form. Biochem Biophys Res Commun 2008, 371(4):855-859.
235. Seo S., Tonda K., Uomori A., Takeda K., Hirata M. Effect of sterol biosynthesis inhibitor, SSF-109, on cholesterol synthesis in isolated rat hepatocytes. Steroids 1993, 58(2):74-78.
236. Seth G., McIvor R.S., Hu W.S. 17Beta-hydroxysteroid dehydrogenase type 7 (Hsd17b7) reverts cholesterol auxotrophy in NS0 cells. J Biotechnol 2006, 121(2):241-252.
237. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333(20):1301-1307.
238. Shitara Y., Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006, 112(1):71-105.
239. Sica D.A., Gehr T.W. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: Considerations in the renal failure patient. Curr Opin Nephrol Hypertens 2002, 11(2):123-133.
240. Siddals K.W., Marshman E., Westwood M., Gibson J.M. Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: Synergy between protein prenylation and receptor glycosylation pathways. J Biol Chem 2004, 279(37):38353-38359.
241. Silve S., Dupuy P.H., Ferrara P., Loison G. Human lamin B receptor exhibits sterol C14-reductase activity in Saccharomyces cerevisiae. Biochim Biophys Acta 1998, 1392(2-3):233-244.
242. Sinensky M., Beck L.A., Leonard S., Evans R. Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 1990, 265(32):19937-19941.
243. Singh I.M., Shishehbor M.H., Ansell B.J. High-density lipoprotein as a therapeutic target: A systematic review. Jama 2007, 298(7):786-798.
244. Stalenhoef A.F., Mol M.J., Stuyt P.M. Efficacy and tolerability of simvastatin (MK-733). Am J Med 1989, 87(4A):39S-43S.
245. Stein E.A. An investigative look: Selective cholesterol absorption inhibitors - embarking on a new standard of care. Am J Manag Care 2002, 8(2 Suppl):S36-S39. discussion S45-37.
246. Stein E.A. Low-density lipoprotein cholesterol reduction and prevention of cardiovascular disease. Mayo Clin Proc 2009, 84(4):307-309.
247. Steinberg D., Avigan J., Feigelson E.B. Effects of triparanol (Mer-29) on cholesterol biosynthesis and on blood sterol levels in man. J Clin Invest 1961, 40(5):884-893.
248. Strömstedt M., Rozman D., Waterman M.R. The ubiquitously expressed human CYP51 encodes lanosterol 14β-demethylase, a cytochrome P450 whose expression is regulated by oxysterols. Arch Biochem Biophys 1996, 329:73-81.
249. Sudhop T., Lutjohann D., Kodal A., Igel M., Tribble D.L., Shah S., et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002, 106(15):1943-1948.
250. Sugawara T., Fujimoto Y., Ishibashi T. Molecular cloning and structural analysis of human sterol C5 desaturase. Biochim Biophys Acta 2001, 1533(3):277-284.
251. Sun L.P., Li L., Goldstein J.L., Brown M.S. Insig required for sterol-mediated inhibition of Scap/SREBP binding to COPII proteins in vitro. J Biol Chem 2005, 280(28):26483-26490.
252. Swinney D.C., So O.-Y., Watson D.M., Berry P.W., Webb A.S., Kertesz D.J., et al. Selective inhibition of mammalian lanosterol 14a-demethylase by RS-2106 in vitro and in vivo. Biochemistry 1994, 33:4702-4713.
253. Szapary P.O., Rader D.J. The triglyceride-high-density lipoprotein axis: An important target of therapy?. Am Heart J 2004, 148(2):211-221.
254. Taguchi N., Rubin E.T., Hosokawa A., Choi J., Ying A.Y., Moretti M.E., et al. Prenatal exposure to HMG-CoA reductase inhibitors: Effects on fetal and neonatal outcomes. Reprod Toxicol 2008, 26(2):175-177.
255. Takahashi M.P., Kimura T., Yanagihara T., Sakoda S. Calcium increase in mouse skeletal muscles by triparanol: A drug to induce myotonic dystrophy-like clinical manifestations. Neurosci Lett 1999, 272(2):87-90.
256. Tall A.R., Yvan-Charvet L., Wang N. The failure of torcetrapib: Was it the molecule or the mechanism?. Arterioscler Thromb Vasc Biol 2007, 27(2):257-260.
257. Tamasi V., Juvan P., Beer M., Rozman D., Meyer U.A. Transcriptional activation of PPARalpha by phenobarbital in the absence of CAR and PXR. Mol Pharm 2009, 6(5):1573-1581.
258. Tandra S., Vuppalanchi R. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med 2009, 11(4):272-278.
259. Tansey T.R., Shechter I. Structure and regulation of mammalian squalene synthase. Biochim Biophys Acta 2000, 1529(1-3):49-62.
260. Taylor A.J., Villines T.C., Stanek E.J., Devine P.J., Griffen L., Miller M., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361(22):2113-2122.
261. Thoma R., Schulz-Gasch T., D'Arcy B., Benz J., Aebi J., Dehmlow H., et al. Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase. Nature 2004, 432(7013):118-122.
262. Tiwari A., Bansal V., Chugh A., Mookhtiar K. Statins and myotoxicity: A therapeutic limitation. Expert Opin Drug Saf 2006, 5(5):651-666.
263. Todd P.A., Goa K.L. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1990, 40(4):583-607.
264. Tuck S.F., Patel H., Safi E., Robinson C.H. Lanosterol 14β-demethylase (P45014DM): Effects of P45014DM inhibitors on sterol biosynthesis downstream of lanosterol. J Lipid Res 1991, 32:893-902.
265. Ugawa T., Kakuta H., Moritani H., Shikama H. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model. Br J Pharmacol 2002, 135(6):1572-1578.
266. Vaklavas C., Chatzizisis Y.S., Ziakas A., Zamboulis C., Giannoglou G.D. Molecular basis of statin-associated myopathy. Atherosclerosis 2009, 202(1):18-28.
267. van Wissen S., Trip M.D., Smilde T.J., de Graaf J., Stalenhoef A.F., Kastelein J.J. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 2002, 165(2):361-366.
268. Vlahakos D.V., Manginas A., Chilidou D., Zamanika C., Alivizatos P.A. Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine. Transplantation 2002, 73(12):1962-1964.
269. Vouk K., Hudler P., Strmsnik L., Fink M., Majdic G., Zorn B., et al. Combinations of genetic changes in the human cAMP-responsive element modulator gene: A clue towards understanding some forms of male infertility?. Mol Hum Reprod 2005, 11(8):567-574.
270. Wassif C.A., Brownson K.E., Sterner A.L., Forlino A., Zerfas P.M., Wilson W.K., et al. HEM dysplasia and ichthyosis are likely laminopathies and not due to 3beta-hydroxysterol Delta14-reductase deficiency. Hum Mol Genet 2007, 16(10):1176-1187.
271. Waterham H.R., Wanders R.J. Biochemical and genetic aspects of 7-dehydrocholesterol reductase and Smith-Lemli-Opitz syndrome. Biochim Biophys Acta 2000, 1529(1-3):340-356.
272. Waterham H.R., Koster J., Romeijn G.J., Hennekam R.C., Vreken P., Andersson H.C., et al. Mutations in the 3beta-hydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. Am J Hum Genet 2001, 69(4):685-694.
273. Whayne T.F. High-density lipoprotein cholesterol: Current perspective for clinicians. Angiology 2009, 60(5):644-649.
274. Wierzbicki A.S. New lipid-lowering agents. Expert Opin Emerg Drugs 2003, 8(2):365-376.
275. Winkler K., Konrad T., Fullert S., Friedrich I., Destani R., Baumstark M.W., et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: A double-blind, placebo-controlled study. Diabetes Care 2003, 26(9):2588-2594.
276. Zarowitz B.J. Are statins safe?. Geriatr Nurs 2007, 28(4):212-217.
277. Zuber C., Spiro M.J., Guhl B., Spiro R.G., Roth J. Golgi apparatus immunolocalization of endomannosidase suggests post-endoplasmic reticulum glucose trimming: Implications for quality control. Mol Biol Cell 2000, 11(12):4227-4240.
278. Zwerger M., Kolb T., Richter K., Karakesisoglou I., Herrmann H. Induction of a massive endoplasmic reticulum and perinuclear space expansion by expression of lamin B receptor mutants and the related sterol reductases TM7SF2 and DHCR7. Mol Biol Cell 2010, 21(2):354-368.